UBS
http://www.ubs.com/UBS provides a range of financial services, including advisory services, underwriting, financing, market making, asset management, brokerage and retail banking on a global level. The Company consists of four divisions: Wealth Management, Asset Management, Investment Banking & Security and Swiss Retail & Corporate Banking. Wealth Management offers high net worth customers advice and investment services, Asset Management offers management solutions for most types of asset class to a range of clients, Investment Banking & Security provides securities, products and research in various areas equities and Swiss Retail & Corporate Banking offers banking and securities services for Swiss clients.
-
Notable Analyst Rating Changes 11/21: (PENN) (THOR) (SKX) Upgraded; (HTWR) (EV) (ICA) Downgraded
-
UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)
-
UPDATE: UBS Downgrades Biogen (BIIB) to Neutral; Risk/Reward Now Balanced
-
UBS Maintains a 'Buy' on Biogen (BIIB); Key Takeaways from 2Q12
-
UBS Maintains a 'Buy' on Biogen (BIIB); Core Franchise Support Valuation; Pipeline Provides Upside Risk
-
UBS Maintains a 'Buy' on Biogen (BIIB); Raising PT on MS Franchise Strength
-
Notable Analyst Rating Changes 09/09: (DB) (SUN) (TWX) Upgraded; (RIMM) (REGN) (SNY) Downgraded
-
UPDATE - UBS Upgraded Biogen (BIIB) to Buy; Reason to Believe in BG-12’s CONFIRM
-
Biogen Idec (BIIB) volatility elevated into UBS upgrade to Buy
-
UBS Upgrades Biogen (BIIB) to Buy
-
UBS Maintains a 'Neutral' on Biogen (BIIB); Updating Model for 2Q
-
UBS Maintains a 'Neutral' on Biogen (BIIB); Raising PT on Best-Case BG-12 Scenario
-
Notable Analyst Rating Changes 04/12: (LVLT) (EIX) (BIIB) Upgraded; (WMS) (AON) (CSX) Downgraded
-
UBS Maintains a 'Neutral' on Biogen (BIIB); Raising Target on BG-12
-
UBS Initiates Coverage on Biogen Idec Inc. (BIIB) with a Neutral; Pipeline Inclusion Likely Would Make Us More Bullish
-
UBS Initiates Coverage on Biotechnology Stocks (CELG, GILD, AMGN & BIIB)
-
UBS Starts Biogen (BIIB) at Neutral
-
Wall Street Hubbub 7/21: Traders Nervous Ahead NFLX/BIDU Results, Dimon & Blankfein Not Welcome at FinReg Signing, Bernanke Set to Testify, BIIB/LLL/DTG In the Rumor Mill
-
A Stock Picker Hits His Stride
-
UBS Maintains a 'Neutral' on Biogen Idec (BIIB); Raises Estimates
-
Notable Analyst Rating Changes 03/09: JEC, YUM, ARRS, YGE Upgraded; FSLR, CMA, ZRAN, CAKE Downgraded
-
Notable Analyst Rating Changes 1/5: RSH, QCOM, BIIB, AXL, More Upgraded; CBY, V, BEXP, COG, CXO, More Downgraded
-
Merriman Curhan Pounds The Table On Facet Biotechnology (FACT) After Board Formally Rejects Biogen Offer
-
Notable Mergers and Acquisitions of the Day 9/22: CBY/KFT, RTP, ATI, FACT/BIIB
-
Facet Biotech's (FACT) Board Makes Recommendation to Shareholders Regarding Biogen Idec's (BIIB) Offer
-
Biogen (BIIB) Elan (ELN) Announced Data Supporting Unique Efficacy of TYSABRI
-
Stocks That Could Rise As Cases Of The Swine Flu Increase (RAD, GENZ, GILD, UTHR, XRAY)
-
Notable Analyst Rating Changes 9/2: TXT, CBE, SI, PAY, BBD Upgraded; ROK, GIS, HOLX, DHI, RYL, NVAX Downgraded
-
Notable Analyst Rating Changes 8/26: STJ, GMR, KMT, CP Upgraded; BKC, AMED, MDAS Downgraded
-
Morning Movers 7/16: BFRM, MOS, SON, CVBF, ONCY Higher; NOK, SLT, RECN, MTG, TRGT Lower
-
Notable Analyst Rating Changes 7/14: BK, UL, VMW, CNK, NILE Upgraded; MNKD, MAS, BKC, VOD Downgraded
-
David Moenning's Daily State of the Markets: 5/8
-
David Moenning's Daily State of the Markets: 2/9
-
Notable Analyst Rating Changes 2/6: UL, TLB, COST, FLIR Upgraded; ABMD, BIIB, ESLR, BKC, MET Downgraded
-
Reports Sanofi-Aventis (SNY) On The Prowl For Mergers
-
Notable Analyst Rating Changes 1/28: BBY, DO, CLX, AFL Upgraded; XOM, CNW, CIEN, UPS Downgraded
-
David Moenning's Daily State of the Markets: 1/27
-
Notable Analyst Rating Changes 1/27: CAT, TXN, BIIB Upgraded; VMW, GNK, DRIV, ADP Downgraded
-
David Moenning's Daily State of the Markets: 01/05
-
David Moenning's Daily State of the Markets: 10/29
-
Notable Analyst Rating Changes 10/29: BIIB, MTH, PCU Upgraded; JNJ, SWIR, ULTI Downgraded
-
UBS Upgrades Biogen Idec (BIIB) to Neutral
-
Notable Analyst Rating Changes 10/28: CHA, BIIB, PHM Upgraded; NOK, NCC, STV, EQ Downgraded
-
Notable Analyst Rating Changes 9/25: BIIB, SAI, COWN Upgraded; JCP, PPC, BWLD Downgraded
-
Pre-Open Movers 7/22: Assured Guaranty (AGO) Sinks On Possible Moody's Downgrade, Foundry Networks (FDRY) Up on Buyout
-
David Moenning's Daily State of the Markets: 7/21
-
Notable Analyst Rating Changes 7/21: BIIB, AMR, AIG, BCSI Upgraded; SWK, TWC, DEO, SHW Downgraded
-
Trading Radar 4/23: Apple (AAPL), Freeport (FCX), Boeing (BA), UPS (UPS), Anheuser-Busch (BUD) Report; Consumer Comfort Index, Crude Inventories Due
-
Notable Analyst Rating Changes 1/17: BIIB, EBAY, NMX Upgraded; JPM, MFE, ADBE, WFC Downgraded
-
David Moenning's Daily State of the Markets: 1/17
